Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Ofatumumab

Summary

Hazard - P - B - T - Risk Exempt

 

This summary information comes from previously published text in Fass. Arzerra (ofatumumab) is now withdrawn from use in Sweden since 2019-02-28.

 

Risk. Exempt.

Fass environmental information

Fass environmental information for Arzerra from Novartis (downloaded 2019-04-24).

Risk

The use of amino acids, proteins and peptides is not considered to have any environmental impact.

Detailed information

According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.

Author: Health and Medical Care Administration, Region Stockholm